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vations over a long period, and outcome in people with type 2
diabetes treated with insulin. METHODS: Data were extracted
from GPRD. An index of glucose variability was generated using
RBG observations over a sustained period (10 years from
insulin initiation) in subjects with 5 RBG observations using
the difference between the maximum and minimum RBG obser-
vation (DMax-MinRBG). Cox proportional hazards models were
developed characterising time to ﬁrst events for: acute myocar-
dial infarction (AMI), stroke, and severe visual loss, as well as for
all-cause mortality. Recognised vascular disease risk factors were
accounted for. RESULTS: There were 4238 subjects who met the
inclusion criteria. The subjects excluded were found to be more
poorly than those included, with shorter follow up and a greater
likelihood of having ever smoked. There was an association
between DMax-MinRBG and HbA1c whereby subjects with good
control were more like to have low variability. Following stan-
dardisation for potentially confounding factors, DMax-MinRBG
(m.mol/l) was associated with all-cause mortality (hazard
ratio [HR] = 1.026 per m.mol/l glucose; p = 0.020); stroke
(HR = 1.046; p < 0.001), and severe visual loss/blindness
(HR = 1.040; p = 0.025). For these three endpoints, DMax-MinRBG
was a better predictor of outcome than was HbA1c, whereas in
AMI, DMax-Min RBG was not signiﬁcant, and HbA1c was
(poor control versus good control: HR = 1.53; p = 0.034). CON-
CLUSION: Although we were unsure why general practitioners
were recording RBG observations, glucose variability over a
sustained period, as measured by DMax-MinRBG, was strongly
associated with all-cause mortality, stroke and vision loss in
people with type 2 diabetes treated with insulin, and more so
than was mean HbA1c over the same extended period.
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OBJECTIVES: Basal insulin administered to type 2 diabetes
patients with poor glycemic control, when managed with oral
therapy alone, can lead to an increased risk of weight gain and
hypoglycemia. A meta-analysis of randomized controlled trials
(RCTs) using treat-to-target protocols was conducted to indi-
rectly compare insulin detemir with insulin glargine on the fol-
lowing outcomes: weight gain, hypoglycemic episodes, and
HbA1c. METHODS: Parallel-group RCTs of at least 20 weeks
duration that compared once-daily glargine or detemir with a
common comparator, NPH insulin (bedtime), in insulin-naïve,
poorly controlled type 2 diabetes patients receiving oral therapy,
were selected. Five open-label trials were identiﬁed (N = 2551
patients; N = 1 detemir and N = 4 glargine trials). A ﬁxed-effects
meta-analysis was used, with an indirect comparison of glargine
(N = 2047 patients) and detemir trials (N = 504 patients) carried
out using meta-regression. Weight gain and mean HbA1c change
from baseline were analyzed as weighted mean differences
(WMD). Mean Hba1c level at study endpoint was analyzed as
standardized mean differences (SMD), and total hypoglycemic
episodes per study were analyzed as odds-ratios (OR). Further
analyses were conducted which adjusted for covariates. Dosing
formulas were comparable across studies. RESULTS: Patients
receiving evening detemir gained signiﬁcantly less weight (unad-
justed WMD -1.22, 95% CI -2.15, -0.29; p = 0.010) and had a
signiﬁcantly lower total number of hypoglycemic episodes versus
evening glargine (unadjusted OR 0.52, 95% CI 0.28, 0.98;
p = 0.044). Mean change from baseline in HbA1c level favored
evening glargine, but there was no signiﬁcant difference between
treatments for mean HbA1c level at study endpoint (unadjusted
SMD 0.09, 95% CI -0.16, 0.33; p = 0.480). CONCLUSION:
Detemir appears similar to glargine in terms of achieving glyce-
mic control, but is superior to the latter for controlling weight
gain and reducing the incidence of hypoglycemic episodes in this
population.
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OBJECTIVES: In the UK, the role of insulin initiation has tradi-
tionally been one for specialist (secondary care) diabetes teams
(SDT) but this trend is changing. The increasing role of primary
care (PC) in diabetes management highlights the need for appro-
priate resource planning. This analysis describes the initial ﬁnd-
ings of a UK primary care audit of patients who were newly
initiated on insulin. METHODS: Data were collected from 8
primary care practices in the UK, covering a total of 58,452
people. Medical records were reviewed to ascertain the preva-
lence of type 2 diabetes mellitus (T2DM), those who initiated
insulin in the last 3 years and associated patient and treatment
details. RESULTS: A total of 2005 patients (3.4%) had a diag-
nosis of T2DM. Insulin was initiated in 316 patients with a mean
age at initiation of 63 years and duration of illness of 8 years. Of
these 149 had been initiated in the last three years (62% PC,
28% SDT) leading to an estimate of annual insulin initiations of
2.19% of all people with type 2 diabetes. The mean HbA1c
closest to insulin initiation was similar for PC (10.6%) and SDT
(10.4%) patients and 54% patients had BMI  30 kg/m2.
Patients commonly initiate insulin following two or more oral
medications (57%), the most common being metformin plus a
sulphonylurea. Pre-mixed insulins and long acting insulin ana-
logues were common, although use differed between PC (59%
long acting insulin analogues) and SDT (49% pre-mixed insulin).
CONCLUSION: In the UK, around 2% of people with T2DM
will be initiated on insulin annually. The majority of these are
initiated within a primary care setting and with HbA1c levels
which are above international clinical targets. Given the trend to
manage more diabetes in primary care, appropriate resources
need to be available to support patients through this intensiﬁca-
tion of therapy.
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OBJECTIVES: To conﬁrm or refute a possible association
between intense Topical Corticosteroid (TC) use and new-onset
diabetes and establish whether it increases with dose and dura-
tion of TC use. METHODS: Data for this nested case-control
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study were obtained from the PHARMO Record Linkage
System, including among others linked drug-dispensing and hos-
pital records of approximately three million individuals in
deﬁned areas of The Netherlands. Users of TC during 1992–
2004, without diabetes, with 4 years of follow-up were
selected. Diabetes onset was deﬁned as ﬁrst occurrence (index
date) of an antidiabetic drug dispensing or hospitalization for
diabetes or diabetes-related diagnoses. Each case was matched
by age and sex to 4 controls without diabetes, with similar
follow-up duration. Use of TC and systemic corticosteroids (SC)
and/or inhaled corticosteroids (IC) as co medication were classi-
ﬁed as current (2 years before index date), recent (4–2 years
ago) and past/never (>4 years ago). Multivariate regression
adjusted for co-medication and co-morbidity. RESULTS: Among
192,893 incident TC users, 2,212 developed diabetes and could
be matched to 8,582 controls. Current TC use was associated
with a 1.24 times increased risk of diabetes (95% CI 1.11–1.40).
The Odds Ratio increased to 1.32 with >180 days of TC use and
to 1.44 with a cumulative TC load (combined potency and units)
731–1,460 mg. Cases more often used SC and IC than controls
(23% versus 17% and 18% versus 13% respectively). Among
“Past/never” users of SC and/or IC, risk of diabetes with current
TC use was 1.25 (95% CI 1.09–1.43); among “Current” users of
SC and/or IC, this OR was 1.13 (95%CI 0.88 1.44). CONCLU-
SION: A statistically signiﬁcant effect of TC use on diabetes was
found. Use of TC as skin treatment among patients at increased
risk of diabetes should be considered with some caution.
DIABETES—Cost Studies
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OBJECTIVES: To implement a ﬂexible PC program to support
decision makers in evaluating the impact of the use of rosiglita-
zone in eligible diabetic patients on the Italian National Health
System budget. METHODS: Rosiglitazone, an insulin-sensitising
drug, is indicated for subjects with inadequate glycaemic control
both as monotherapy, in those contraindicated to metformin
(especially if overweight) and as combination therapy with met-
formin, sulphonylureas or both. The software developed has a
user-friendly interface and is based on an analytic model, which
pathway may be summarized as follows: a) estimate of the
number of Italian type 2 diabetes patients, grouped according to
current therapeutic classes; b) estimate of the number of patients
with inadequate glycaemic control for each subgroup; c) identi-
ﬁcation of patients eligible to rosiglitazone treatment; d) identi-
ﬁcation of the comparator strategy for each patient sub-group; e)
comparison of costs for each couple of alternative options; and f)
calculation of budget impact. The user can modify most default
data to adapt the analysis to the speciﬁc setting. RESULTS:
Default data based scenario shows that adoption of rosiglitazone
monotherapy induces a mild cost increase. Combination treat-
ments induce signiﬁcant cost savings, related to lower resource
consumption for glycaemic auto-monitoring and hypoglycaemia
management, as compared to standard combination therapies.
The hypothetical scenario in which all eligible Italian patients are
treated with rosiglitazone is estimated to induce net savings for
about 260 millions Euro per year. CONCLUSION: In type 2
diabetes, the maintenance of non-diabetic glycaemic levels has
been shown to decrease the onset of long term complications.
Rosiglitazone represents a further option to postpone insulin
therapy start with a potential cost-saving for the Italian National
Heath System.
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OBJECTIVES: To estimate the economic inefﬁciency of bad
control of Diabetes in terms of direct cost in diabetic patients in
a rural area in Spain (Axarquía) during one-year of follow up.
METHODS: Cohort study of 228 patients (2 rural health centres
sampled in 2005–2006). The perspective analysis was National
Health System. Total cost is composed of four items: insulin and
oral hypoglycaemic agents, glycosylated haemoglobin, dispos-
able and consumable goods (glucose test strips, needles, and
syringes) and primary care visits. The statistical analysis was
made by the SPSS package. For quantitative: mean, DS, IC95%;
for qualitative: proportions. For inferential statistics: Student’s
T-test for quantitative variables and test of Chi-square for the
qualitative ones. Multivariante analysis considered: age, gender,
control grade (ADA, 2006) and interaction gender-control of
DM. The ratio cost-effectiveness and incremental cost of control
compared with non-control of DM was analized with WinBugs
controlled for age and gender. RESULTS: Sixty-seven percent of
females; average age: 69 years. The average of prescribed drugs
for DM control was 1.4 drugs/per patient (1.03% acarbose;
32.99% sulphonylurea; 64.43% biguanide, 13.40% metiglinide
and the 27.32% insuline). The mean of primary care visits
was 14.8/per patient/year. The Diabetes control was 68%
(HbA1c% < 7) with 1.34 drugs per year in controlled patients
versus 1.61 drugs in non-controlled (p < 0.01). The direct health
care cost of diabetic patient was €628/year (CI95%: €576–680).
In patients non haemoglobin glycosilated controlled the cost was
incremented in €193 per patient and the effectiveness decal in
32%. CONCLUSION: This economic study demonstrates the
real possibility to improve the efﬁciency of our interventions. If
we transferred the data found to our area of reference (Málaga)
the saving in costs would be superior to €3 million. Health
providers and policymakers should use this information in
making clinical and policy decisions in order to use resources
efﬁciently.
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OBJECTIVES: To evaluate 2-year real world outcomes of glyce-
mic control in patients with T2DM initiating insulin glargine vs.
NPH insulin. METHODS: Patients with T2DM (March 2001–
March 2005) who failed oral antidiabetic agents, initiated
glargine (n = 2105) or NPH (n = 734), with continuous plan
enrollment for >18 months (6 months (baseline) prior to and 12
months after insulin initiation) and with available laboratory
HbA1C values, were evaluated using a US managed care claims
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